Table 1 The clinical characteristics of the patients
Characteristics | No. (%) or mean ± SD |
|---|---|
Cases (eyes) | 72 (87) |
Gender | |
Male | 37 (51.4) |
Female | 35 (48.6) |
Age (years) | 71.50 ± 9.11 |
Hypertension | 34 (47.2) |
Diabetes | 11 (15.3) |
Cataract surgery | 21 (24.1) |
Baseline VMIA | 43 (49.4) |
VMA broad | 14 (16.1) |
VMA focal | 15 (17.2) |
ERM | 14 (16.1) |
Anti-VEGF | |
Conbercept | 58 (66.7) |
Ranibizumab | 29 (33.3) |
Total injection times | 4.41 ± 2.60 |
Follow-up (months) | 9.09 ± 8.07 |
Baseline BCVA (Log MAR) | 1.01 ± 0.44 |
Final BCVA (Log MAR) | 0.87 ± 0.44 |
Baseline CRT(µm) | 447.11 ± 198.65 |
Final CRT(µm) | 316.06 ± 198.24 |
Total incidence of VMI change | 9 (10.3) |
First injection to VMI change (months) | 4.00 ± 3.64 |